Mansi L, Di Lieto E, Rambaldi P F, Bergaminelli C, Fallanca F, Vicidomini G, Cuccurullo V, Mancusi R
Istituto di Chirurgia Toracica e Metodologia Clinica, II Università degli Studi, Napoli.
Minerva Chir. 1998 May;53(5):369-72.
Radioimmunoguided surgery (RIGS) can be a valid option in the management of lung cancer as well as neoplasms in other anatomic sites.
We evaluated the usefulness of radioimmunoguided surgery (RIGS) in the staging of primitive non small cell lung cancer. Intraoperatively, this technique can define the lymph nodes involvement and thus, the radicality of the resection. In the first stage of our study, we looked for the epitope TAG 72 in 45 patients with primary non small cell lung cancer. The epitope was found by immunochemistry in only 6 cases. The only one operable patient was injected with monoclonal antibody B 72.3, that was 125I-labelled.
At the operation, the monoclonal antibody showed no selectivity for neoplastic cells. Neoplastic tissue and healthy tissue showed a similar detection of the monoclonal antibody both intraoperatively and at the histochemical study. Because of the problems related with this method--e.g. technical difficulties, excessive wasting of time and lack of imaging--we modified our strategy. In this second stage of our study we used fragments of murine anti-CEA monoclonal antibody F023C5. The protocol was performed in 11 patients with squamous cell lung cancer. In one patient operated on for an excavated cancer(not well-defined at the immunoscintigraphy) intraoperative detection was negative while the ex vivo counts were significant: the neoplastic tissue showed a radioactivity twice higher than healthy tissue. Furthermore, the RIGS found a small intraparenchimal lymph node that was seen neither by CT nor by immunoscintigraphy.
Our data are still preliminary, but with improvement of the technique and the use of more specific monoclonal antibodies the RIGS could become a helpful method, able to improve the radicality of surgery for lung cancer.
放射免疫导向手术(RIGS)在肺癌以及其他解剖部位肿瘤的治疗中可能是一种有效的选择。
我们评估了放射免疫导向手术(RIGS)在原发性非小细胞肺癌分期中的作用。术中,该技术可确定淋巴结受累情况,从而确定切除的彻底性。在我们研究的第一阶段,我们在45例原发性非小细胞肺癌患者中寻找表位TAG 72。仅在6例患者中通过免疫化学发现了该表位。唯一可手术的患者注射了125I标记的单克隆抗体B 72.3。
手术时,单克隆抗体对肿瘤细胞无选择性。肿瘤组织和健康组织在术中及组织化学研究中对单克隆抗体的检测相似。由于该方法存在相关问题,如技术困难、时间浪费过多和缺乏成像,我们修改了策略。在研究的第二阶段,我们使用了鼠抗CEA单克隆抗体F023C5的片段。该方案在11例鳞状细胞肺癌患者中实施。在1例因空洞性癌接受手术的患者中(免疫闪烁显像时边界不清),术中检测为阴性,但体外计数显示有意义:肿瘤组织的放射性比健康组织高两倍。此外,RIGS发现了一个小的实质内淋巴结,CT和免疫闪烁显像均未发现。
我们的数据仍然是初步的,但随着技术的改进和使用更特异的单克隆抗体,RIGS可能会成为一种有用的方法,能够提高肺癌手术的彻底性。